Literature DB >> 11708988

The genetic and pathological classification of familial frontotemporal dementia.

H R Morris1, M N Khan, J C Janssen, J M Brown, J Perez-Tur, M Baker, M Ozansoy, J Hardy, M Hutton, N W Wood, A J Lees, T Revesz, P Lantos, M N Rossor.   

Abstract

BACKGROUND: Frontotemporal dementia (FTD) is an important cause of neurodegenerative dementia, particularly in younger patients. TAU has been identified as the gene responsible for FTD linked to chromosome 17, but it is likely that there is pathological and genetic heterogeneity among families with FTD.
OBJECTIVE: To explore the genetic and pathological basis of familial FTD.
DESIGN: Clinical case series with genetic analysis of each family, and pathological confirmation of diagnosis where possible.
SETTING: Specialist dementia research group, particularly recruiting patients with young-onset dementia. PATIENTS: Twenty-two families with an index member with FTD, meeting Lund-Manchester criteria, and a family history of other affected members with dementia were ascertained.
RESULTS: Half of the families had mutations in the TAU gene (TAU exon 10 +14, +16, and P301S), and pathological diagnoses were available in 17 of 22 families. Three main pathological diagnoses were made: FTD with neuronal and glial tau deposition, FTD with ubiquitin inclusions, and FTD with neuronal loss and spongiosis but without intracellular inclusions. No cases of familial Pick disease were identified. With the use of the pathological diagnoses, each family with FTD with neuronal and glial tau deposition had a TAU mutation, whereas TAU mutations were not identified in families in the other 2 diagnostic groups.
CONCLUSIONS: This study illustrates the value of TAU sequencing in FTD and suggests that around one half of individuals with familial FTD have TAU mutations and dementia with tau pathological findings. Furthermore, these data suggest that there are at least 2 additional genes to be identified among families with autosomal dominant FTD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11708988     DOI: 10.1001/archneur.58.11.1813

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  18 in total

1.  Familial autosomal dominant cortico-basal degeneration with the P301S mutation in the tau gene: an example of phenotype variability.

Authors:  W Casseron; J P Azulay; E Guedj; J L Gastaut; J Pouget
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

2.  Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy.

Authors:  Rosa Capozzo; Celeste Sassi; Monia B Hammer; Simona Arcuti; Chiara Zecca; Maria R Barulli; Rosanna Tortelli; J Raphael Gibbs; Cynthia Crews; Davide Seripa; Francesco Carnicella; Claudia Dell'Aquila; Marco Rossi; Filippo Tamma; Francesco Valluzzi; Bruno Brancasi; Francesco Panza; Andrew B Singleton; Giancarlo Logroscino
Journal:  Alzheimers Dement       Date:  2017-03-03       Impact factor: 21.566

Review 3.  The genetics of frontotemporal lobar degeneration.

Authors:  Rosa Rademakers; Mike Hutton
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

4.  Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration.

Authors:  Albert Lladó; Raquel Sánchez-Valle; Maria Jesús Rey; Mario Ezquerra; Eduardo Tolosa; Isidro Ferrer; José Luis Molinuevo
Journal:  J Neurol       Date:  2008-03-25       Impact factor: 4.849

5.  Patient care and management of frontotemporal lobar degeneration.

Authors:  Lauren Massimo; Murray Grossman
Journal:  Am J Alzheimers Dis Other Demen       Date:  2008 Apr-May       Impact factor: 2.035

6.  Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies.

Authors:  Prudence M Stanford; William S Brooks; Erdahl T Teber; Marianne Hallupp; Catriona McLean; Glenda M Halliday; Ralph N Martins; John B J Kwok; Peter R Schofield
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

7.  Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.

Authors:  Magali Dumont; Cliona Stack; Ceyhan Elipenahli; Shari Jainuddin; Meri Gerges; Natalia Starkova; Noel Y Calingasan; Lichuan Yang; Davide Tampellini; Anatoly A Starkov; Robin B Chan; Gilbert Di Paolo; Aurora Pujol; M Flint Beal
Journal:  Hum Mol Genet       Date:  2012-08-24       Impact factor: 6.150

8.  Obesity, diabetes, and leptin resistance promote tau pathology in a mouse model of disease.

Authors:  T L Platt; T L Beckett; K Kohler; D M Niedowicz; M P Murphy
Journal:  Neuroscience       Date:  2015-12-14       Impact factor: 3.590

9.  Role of MAPT mutations and haplotype in frontotemporal lobar degeneration in Northern Finland.

Authors:  Anna-Lotta Kaivorinne; Johanna Krüger; Katja Kuivaniemi; Hannu Tuominen; Virpi Moilanen; Kari Majamaa; Anne M Remes
Journal:  BMC Neurol       Date:  2008-12-17       Impact factor: 2.474

Review 10.  Mechanism-based treatments for Alzheimer's disease.

Authors:  Peter Davies; Jeremy Koppel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.